Formulation development, in-vitro and ex-vivo evaluation of dry adsorbed solid lipid nanoparticles: an approach of overcoming olanzapine drawbacks.

The present study was aimed at preparing stable dry adsorbed nanoparticles (DANs) of olanzapine (OLZ) loaded solid lipid nanoparticles (SLNs) for sustained release. OLZ SLNs were prepared by hot melt emulsification and ultrasonication using Precirol ATO 5 (PRE) as a solid lipid, combination of Kolli...

Descripción completa

Detalles Bibliográficos
Publicado en:European Pharmaceutical Journal Vol. 71; no. 1; pp. 1 - 16
Autores principales: Hirlekar, Rajashree, Momin, Alfiha, Bhairy, Srinivas
Formato: equations & formulas pictorial research tables/charts Journal Article
Publicado: Paradigm Publishing Services Aug2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=179147444&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 179147444
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        24536725
        LF1O
      jtl: European Pharmaceutical Journal
      issn: 24536725
      maglogo: N
    pubinfo:
      dt: Aug2024
      vid: 71
      iid: 1
      pid: 35924
      pub: Paradigm Publishing Services
    artinfo:
      ui:
        179147444
        176664382
        179147444
        179147444
        10.2478/afpuc-2024-0004
        179147444
      ppf: 1
      ppct: 15
      formats:
      tig:
        atl: Formulation development, in-vitro and ex-vivo evaluation of dry adsorbed solid lipid nanoparticles: an approach of overcoming olanzapine drawbacks.
      aug:
        au:
          Hirlekar, Rajashree
          Momin, Alfiha
          Bhairy, Srinivas
        affil: Vivekanand Education Society's College of Pharmacy, Mumbai, Maharashtra INDIA
      sug:
        subj:
          Olanzapine Europe
          Lipids
          Nanoparticles
          Adsorption
          Drug Development
          Chemistry, Pharmaceutical
          Drug Efficacy
          Biological Availability
          Permeability
          In Vitro Studies
          In Vivo Studies
          Ultrasonics
          Surface-Active Agents Analysis
          Particle Size
          Olanzapine Pharmacodynamics
          Animal Studies
          Poultry
          Liver Metabolism
          X-Rays
          Dosage Forms
          Nanotechnology
          Drug Delivery Systems
          Olanzapine Pharmacokinetics
          Intestinal Absorption
          Administration, Oral
          Spectrophotometry
          Microscopy, Electron, Scanning
          Calorimetry
          Europe
          Lipids Blood
      ab: The present study was aimed at preparing stable dry adsorbed nanoparticles (DANs) of olanzapine (OLZ) loaded solid lipid nanoparticles (SLNs) for sustained release. OLZ SLNs were prepared by hot melt emulsification and ultrasonication using Precirol ATO 5 (PRE) as a solid lipid, combination of Kolliphor ELP (KELP) and Tween 80 (T80) as surfactants, after optimising formulation and process variables. The SLN system was subjected to evaluation of particle size, zeta potential, entrapment efficiency (EE), in-vitro drug release and ex-vivo intestinal permeability studies using the chicken intestinal segments (jejunum). Further, these SLNs were converted into stable DANs by adsorbing onto a Neusilin US2 (NUS2) and Avicel CL 611 (ACL) carriers using the granulation-evaporative drying method. The DANs were characterised for redispersion properties, in-vitro drug release, thermal behaviour, crystallinity, and morphology. The SLN and DAN had a particle size of 238.0 nm [0.274 polydispersity index (PdI)] and 302.4 [0.494 PdI] respectively. The zeta potentials of SLN and DAN were found to be −29.3 mV and −26.3 mV, respectively. The SLN had 67% EE, and showed a sustained drug release in various media. The highest permeability of SLNs was observed in ex-vivo permeation model compared to the OLZ suspension, indicating that SLNs have the potential to bypass hepatic metabolism. The adsorption of SLNs onto carriers was confirmed by surface morphology. The DAN had good flow properties and sustained drug release similar to that of SLNs. The X-ray diffraction (XRD) patterns and endothermic peaks confirmed the complete encapsulation of actives in lipid matrices. The encapsulating of OLZ in SLNs and converting it into DAN showed a sustained release and adsorption technique that can be used for improving the stability of NLC dispersion. The DANs can be offered in dosage forms such as filling into sachets, capsules and compressed into tablets.
      pubtype: Academic Journal
      doctype:
        equations & formulas
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N